# Prothena (stock symbol: PRTA) Logo in transparent PNG and SVG formats

## Prothena Logo large

### Prothena Logo large Download PNG (51.2 KB)

![Prothena Logo large Download PNG (51.2 KB)](/img/orig/PRTA_BIG-eeb8d07e.png)

### Prothena Logo large Download SVG (30.33 KB)

![Prothena Logo large Download SVG (30.33 KB)](/img/orig/PRTA_BIG-4909ff3e.svg)

## Prothena Logo icon format

### Prothena Logo icon format Download PNG (64.1 KB)

![Prothena Logo icon format Download PNG (64.1 KB)](/img/orig/PRTA-7b115e16.png)

### Prothena Logo icon format Download SVG (2.18 KB)

![Prothena Logo icon format Download SVG (2.18 KB)](/img/orig/PRTA-f2880172.svg)

## About Prothena

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual AÃŸ-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.

1. Website domain: prothena.com
2. Employees: 82
3. Marketcap: $2.76 Billion USD


## Categories
- [x] ðŸ‡®ðŸ‡ª Ireland
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
